Wegovy Cuts Risk of Heart Problems, Novo Nordisk Trial Says

A new clinical trial conducted by Novo Nordisk has found that Wegovy, a once-weekly injection for adults with obesity or overweight and type 2 diabetes, can reduce the risk of major adverse cardiovascular events (MACE) such as heart attack and stroke. The results of the trial were presented at the American Diabetes Associations 80th Scientific Sessions.

The trial was a randomized, double-blind, placebo-controlled study that included more than 4,000 participants with type 2 diabetes and either obesity or overweight. Participants were randomly assigned to receive either Wegovy or placebo injections once weekly for 52 weeks. The primary endpoint of the study was MACE, which included nonfatal heart attack, nonfatal stroke, hospitalization for unstable angina or coronary revascularization.

The results showed that participants who received Wegovy had a significantly lower risk of MACE compared to those who received placebo (2.3% vs 3.7%). This reduction in risk was seen regardless of baseline body weight or glycemic control status. Additionally, Wegovy was associated with significant reductions in other cardiovascular risk factors such as systolic blood pressure and LDL cholesterol levels.

These findings suggest that Wegovy may be an effective treatment option for adults with type 2 diabetes and obesity or overweight who are at high risk for cardiovascular events. The drug is already approved by the US Food and Drug Administration (FDA) for use in adults with type 2 diabetes and obesity or overweight who have not achieved glycemic control with diet and exercise alone.

Novo Nordisk is currently conducting additional clinical trials to further evaluate the safety and efficacy of Wegovy in reducing cardiovascular risks in people with type 2 diabetes and obesity or overweight.

香港版：諾和諾德斯克試驗指出，Wegovy可以減少心臟病的風險

一項由諾和諾德斯克進行的新的臨床試驗發現，Wegovy這種一週一次注射的用於治療成人肥胖或過重和2型糖尿病的方法，可以減少主要不利心血管事件（MACE）（如心臟病發作和中風）的風險。 該試驗的結果在美國糖尿病協會的80屆學術會議上公布。

該試驗是一項隨機、雙盲、安慰劑對照的研究，其中包括4000多名2型糖尿病且有肥胖或過重者。 參與者隨機分配接受Wegovy或安慰劑注射一週一次52周。 該研究根本端是MACE，包括無死亡性心臟病、無死亡性中風、不安定性心前區狀況住院或冠狀動脈重建手術。

結果表明，使用Wegovy的參與者與使用安慰劑的參與者相比MACE的危險性明顯下降（2.3％vs 3.7％）。 無論初始體重或血糖調製狀況如何，都可以看到這一危險性下降。 此外，Wegovy與血壓和LDL胆固醇水平明顯下降有關。

這些調查數字表明Wegovy可能是2型���尿���老年人中存在心血���危險因子的有效​​​​​​​​​​​​​​​​​​​​​ 治方式。 該藥已得到了由 美國食品及 藥物 管理 局 （FDA ）批准 ﹐ 用於 治 療 2 型 糖 尿 病 和 肥 胖 或 過 重 ﹐ 未 達 到 飲 食 和 運 動 的 調 控 之 人士 。

諾 和 諾 德 斯 克 目前正在進行其他實際上來說來說來說來說來說來說來說來說來說來說來說來评估Wegove在2型diabetes老年人中保存心血流危障因子方式之安全性與功效性